Develops RNA-based medicines for genetic epilepsy.
Jun 2026Revenue $27.6M/yrExpenses $251M/yr
No trendCash runway ≈ 1.6 years from Jun 2026
Figures by year
When will Stoke Therapeutics be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Jun 2026, revenue was $27.6M and expenses $251M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $184M | $205M | −$20.6M |
| Dec 2024 | $36.6M | $138M | −$101M |
| Dec 2023 | $8.78M | $124M | −$115M |
| Dec 2022 | $12.4M | $117M | −$104M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.